Loading…
Loading…
SYNB (Putnam BioRevolution ETF) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
See exactly how SYNB's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SYNB and 80,000+ other tickers.
This exchange-traded fund (ETF) primarily allocates its capital to common equity securities issued by companies globally, irrespective of their market capitalization. Its central investment theme revolves around enterprises driving the "biology revolution," whether they are classified as growth-oriented, value-based, or a blend of both. Periodically, the fund may dedicate a substantial segment of its assets to firms operating within one or more interconnected industries or sectors. These could encompass areas such as healthcare, consumer discretionary, consumer staples, biotechnology, and materials. As a non-diversified fund, its portfolio may exhibit higher concentration.
SAN MATEO, Calif.--(BUSINESS WIRE)--Franklin Templeton today announced it will liquidate and dissolve Putnam BioRevolution™ ETF (SYNB). The liquidation is anticipated to occur on or about November 21, 2025, although the Fund may make dispositions of portfolio holdings prior to the liquidation date. Effective as of the close of business on October 24, 2025, the Fund will no longer accept orders for the purchase of creation units, and effective as of the close of business on November 13, 2025, th.
Putnam Investments announced that on Friday, September 30, it will launch two new transparent, actively managed, equity exchange traded funds: the Putnam BDC Income ETF (NYSE Arca: PBDC), concentrating on business development companies (BDCs), and the Putnam BioRevolution ETF (NYSE Arca: SYNB), centered on companies operating at the intersection of technology and biology in the “biology revolution.